Storyline
Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal for in vivo cell therapy
Eli Lilly has agreed to acquire Kelonia Therapeutics, a cancer drug maker developing an in vivo CAR-T cell therapy currently in phase 1 trials for multiple myeloma. The deal is worth up to $7 billion, including $3.25 billion in upfront cash.
Published 2026-04-20 14:18 UTCUpdated 2026-04-21 00:16 UTC
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Eli Lilly has agreed to acquire Kelonia Therapeutics, a cancer drug maker developing an in vivo CAR-T cell therapy currently in phase 1 trials for multiple myeloma. The deal is worth up to $7 billion, including $3.25 billion in upfront cash.
Score total
1.56
Momentum 24h
3
Posts
3
Origins
3
Source types
2
Duplicate ratio
0%
Why now
- Kelonia's therapy is in early-phase clinical trials, making it a timely acquisition.
- Lilly is accelerating its investment in innovative cancer treatments this year.
- The deal follows Lilly's recent acquisition of another in vivo cell therapy company, signaling a trend.
Why it matters
- Strengthens Lilly's position in the emerging in vivo CAR-T therapy field.
- Targets multiple myeloma, a cancer with significant unmet medical need.
- Highlights Lilly's strategic focus on early-stage cell therapy development.
Continuity snapshot
- Trend status: insufficient_history.
- Continuity stage: emerging_confirmed.
- Current status: open.
- 3 current source-linked posts are attached to this storyline.
All evidence
All evidence
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
biotech · cnbc.com · 2026-04-21 00:16 UTC
Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout
BioPharma Dive · biopharmadive.com · 2026-04-20 15:14 UTC
Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia Therapeutics and its phase 1-stage myeloma therapy.
Fierce Biotech · fiercebiotech.com · 2026-04-20 14:18 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- biotech (1)
- BioPharma Dive (1)
- Fierce Biotech (1)
Top origin domains (this list)
- cnbc.com (1)
- biopharmadive.com (1)
- fiercebiotech.com (1)